H.R. 6832 explained · 117th Congress · Not enacted (117th Congress ended)
To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
Introduced: 2022-02-25
Latest action (2022-02-28): Referred to the Subcommittee on Health.
What H.R. 6832 does, in plain terms
The Congressional Research Service has not published a summary of H.R. 6832 yet. Its official title: “To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.”.
Constitution Index
“VFA Constitution grade”
Not graded yet
H.R. 6832 has not been graded yet. New measures with an official summary are graded daily under the published rubric.
What should pass
“VFA SI Solution”
No solution yet
A sourced SI draft appears here once it passes automated checks (Constitution citation, source verification, independent SI critic). How publication works.
For journalists and bloggers
“Embed this grade”
Free to use with the link back. The badge and card update when the grade changes. Embed terms →
